Startup profile · funding coverage
Patch Biosciences funding, valuation and investors
Patch Biosciences developed programmable DNA medicines before the biotech wound down or was acquired.
Keep track of Patch Biosciences
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
Amount not disclosed · August 2020
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
acquired
acquired · New York, NY
Investors in latest funding
Other: Andreessen Horowitz
Overview
Patch Biosciences built an AI platform for programmable genetic medicine sequence design — synthetic promoters and UTR engineering for gene therapy, cell therapy, and RNA therapeutics. a16z Bio + Health backed the company alongside Casdin Capital and S32. Ginkgo Bioworks acquired Patch in February 2024, integrating its ML models into Ginkgo's genetic medicine R&D services.
Why Patch Biosciences is interesting
A synthetic-biology play in the a16z bio portfolio targeting programmable therapeutics — early-stage platform for gene-level drug design.
Product & use cases
AI/ML models and assays for designing promoters, UTRs, and genetic medicine cargos with validated muscle promoters and RNA elements.
- Synthetic promoter design for gene therapy
- UTR optimization for RNA therapeutics
- Genetic medicine R&D services via Ginkgo post-acquisition
Key facts
- a16z portfolio status: Exit
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24
Funding history (newest first)
Seed
2020-08Source: https://www.cbinsights.com/company/patch-biosciences/financials
Investors in our directory
Funds linked from Patch Biosciences's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: ML-driven sequence design with validated genetic assets versus manual construct engineering.
Patch sold to Ginkgo rather than scale as standalone therapeutics company — tech became part of Ginkgo's service stack.
-
Ginkgo Bioworks incumbent
Acquirer; now hosts Patch capabilities as services.
-
Asimov adjacent
Genetic circuit design platform.
-
Manual CRO design alternative
Traditional lab iteration; slower.
Notable stories
- Ginkgo paid ~$4.3M in RSUs to eight Patch employees per FierceBiotech reporting on the 2024 deal.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Patch Biosciences's financing or category context.
FAQs about Patch Biosciences
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.